Your browser doesn't support javascript.
loading
Long-Term Withdrawal of Anticoagulation and Antiplatelet Therapy in a HeartMate 3 Left Ventricular Assist Device.
Menchaca, Kristina; Ostos Perez, Catherine A; Draguljevic, Nemanja; Paciletti, Jennifer; Ghumman, Waqas; Faber, Cristiano; Mirza, Sajid.
Afiliação
  • Menchaca K; Internal Medicine, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
  • Ostos Perez CA; Internal Medicine, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
  • Draguljevic N; Internal Medicine, University of Belgrade, Belgrade, SRB.
  • Paciletti J; Cardiology, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
  • Ghumman W; Internal Medicine, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
  • Faber C; Cardiology, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
  • Mirza S; Cardiology, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
Cureus ; 14(9): e28779, 2022 Sep.
Article em En | MEDLINE | ID: mdl-36111326
ABSTRACT
A 73-year-old male with end-stage heart failure underwent insertion of the HeartMate 3 (Abbott, North Chicago, IL, USA) device. Systemic anticoagulation and antiplatelets were discontinued for 52 days due to postoperative bleeding. After hemorrhage resolution, we restarted warfarin monotherapy targeting an international normalized ratio of 1.8-2.5. Eight months later, there are no reports of pump thrombosis, thromboembolism, and bleeding.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article